
AR Reporting: Rules for an Isolate

#### **CALCULATION WALKTHROUGH**





## Eligible Organisms

- Full List: Appendix A, NHSN AUR Guide
- Antimicrobials required for resistance testing

Organism	Specimen Type	Antimicrobial Agents
Acinetobacter	Blood, Urine, Lower	Amikacin
(All Acinetobacter species	Respiratory, CSF	Ampicillin-sulbactam
noted in the IDM/Pathogen		Cefepime
Codes tab listed in the		Cefotaxime
ARO Pathogen column)		Ceftazidime
		Ceftriaxone
		Ciprofloxacin
		Doxcycline
		Gentamicin
		Imipenem with Cilastatin
		Levofloxacin
		Meropenem
		Minocycline
		Piperacillin
		Piperacillin-tazobactam
		Tetracycline
		Ticarcillin-clavulanate
		Tobramycin
		Trimethoprim-sulfamethoxazole
	Additional Agents for Urine	None



#### Eligible Isolates

- Report all required data each month for each eligible isolate-based report
- Inpatient or specific outpatient locations (i.e., ED, pediatric ED, and 24-hour observation)
- Regardless of antimicrobial resistance
  - susceptible to all required antimicrobials



#### Lab Reporting Guidelines

- Interpretation of test results (i.e., E-test, MIC test, Disk diffusion [KB] test):
  - S = Susceptible
  - S-DD = Susceptible-Dose Dependent
  - I = Intermediate
  - R = Resistant
  - NS = Non-Susceptible
  - N = Not Tested
- Specific to Gentamicin and Streptomycin results for Enterococcus testing:
  - S = Susceptible/Synergistic
  - R = Resistant/Not Synergistic
- Facilities should only report final or corrected susceptibility testing.



#### Electronic Calculation Requirement

- Facilities should not employ manual data collection to report AR.
- Facilities that cannot electronically obtain the results of the individual laboratory tests should:
  - Use 'Unknown' or 'Not Tested'
  - Provide the final interpretation result



#### Specimen Types

- Two distinct sources are reported:
  - Invasive Specimen: Blood or cerebrospinal fluid
  - Non-Invasive Specimen: Lower respiratory or urine
- Different sources, different "AR Events"



#### Reporting Rules for Specimen Sources

#### Invasive Sources

Each eligible organism isolated from an invasive source (i.e., blood or CSF) per patient, per 14-day period, across calendar months

#### Non-Invasive Sources

First eligible organism isolated from an eligible noninvasive culture source (i.e., lower respiratory or urine), per patient, per month



## Reporting for Non-Required Drugs

- Isolate is eligible for reporting if:
  - All of the NHSN required antimicrobials were not tested
  - At least one non-required drug is eligible
- Example:
  - Oritavancin is not a required antimicrobial for the Staphlococcus aureus isolate
  - None of the 23 required antimicrobials were tested
  - Isolate is still considered eligible for reporting



## Reporting for Non-Required Drugs

- For such an isolate, the facility will:
  - Report the specimen.
  - Report "Not Tested" for all required drugs.
  - Exclude the susceptibility information for
     Oritavancin because it not in the drug panel for that organism.



#### Thank You

- Invasive Steps
- Non-Invasive Steps
- Deduplication
- Full Overview




AR Reporting: Rules for reporting an Isolate from an invasive source

#### **CALCULATION WALKTHROUGH**



Numerator Reporting: Invasive Steps patient for the last month



**Public**Health

Collect isolates for

## **Invasive Specimen Reporting**

- Record an AR Event for:
  - Each eligible organism isolated from an invasive source (i.e., blood or CSF)
  - Per patient
  - Per 14-day period
  - Across Calendar Months
- The 14-day Rule for Invasive Specimens:
  - Record an AR Event after 14 days with no positive culture result from the laboratory if the patient and specific organism pass.




#### 14 Day Rule

- Additional Guidance for the 14 day Rule:
  - Count starts on the day of specimen collection
  - Only applies to those specimens from an inpatient location or select outpatient location (i.e., ED, pediatric ED, or 24-hour observation area)
  - Exclude cultures from other healthcare facilities
- At a maximum, there will be no more than three invasive isolates per specific organism per patient per month.



## Algorithm for Invasive Specimen





Date	Source	Antimicrobial Agent	Test	Results	Antimicrobi al agent	Test	Results
2018- 02-20	Blood	Sulfamethoxazole with	E-test	Greater than 5.0 ug/ml Resistant	Ceftazidime	E-test	Less than 0.1 ug/ml Susceptible
		Trimethoprim	Disk Lufft			Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate
						Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible
			Final nte			Final Interpretation	Susceptible
2018- 02-24	CSF	Chloramphenicol	E-test	Susceptible	vofloxacin	E-test	Less than 0.1 ug/ml Susceptible
			Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	N/A		Minimum inhibitory concentration (MIC)	N/A
			Final Interpretation	Susceptible		Final Interpretation	Susceptible
2018- 03-16	Blood	Minocycline	E-test	Less than 0.1 ug/ml Susceptible	Ceftazidime	E-test	Greater than 5.0 ug/ml Resistant
			Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate		Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible		Minimum inhibitory concentration (MIC)	N/A
			Final Interpretation	Susceptible		Final Interpretation	Resistant

Date	Source	Antimicrobial Agent	Test	Results Oort to NHSN	Antimicrobi l agent	Test	Results
2018- 02-20	Blood	Sulfamethoxazole with	c-test This is	s the first blood	eftazidime	E-test	Less than 0.1 ug/ml Susceptible
		Trimethopam	Disk Diff	e collected for		Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate
			Minimur t	his patient		Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible
			Final Interpretation	Resistant		Final Interpretation	Susceptible
2018- 02-24	CSF	Chloramphenicol	E-test	Less than 0.1 ug/ml Susceptible	Levofloxacin	E-test	Less than 0.1 ug/ml Susceptible
			Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	N/A		Minimum inhibitory concentration (MIC)	N/A
			Final Interpretation	Susceptible		Final Interpretation	Susceptible
2018- 03-16	Blood	Minocycline	E-test	Less than 0.1 ug/ml Susceptible	Ceftazidime	E-test	Greater than 5.0 ug/ml Resistant
			Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate		Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible		Minimum inhibitory concentration (MIC)	N/A
			Final Interpretation	Susceptible		Final Interpretation	Resistant

Date	Source	Antimicrobial Agent	Test		Results	Antimicrobi al agent	Test	Results
2018- 02-20	Blood	Sulfamethoxazole with Trimethoprim	E-test		Greater than 5.0 ug/ml Resistant	Ceftazidime	E-test	Less than 0.1 ug/ml Susceptible
			Disk Diffusion (	KB)	N/A		Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate
			Minimum inhik		N/A		Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible
		Final Int	o no	t report to NHSN		Final Interpretation	Susceptible	
2018- CSF 02-24	Chloramphenico	E-test   It	It has been less than 14		evofloxacin	E-test	Less than 0.1 ug/ml Susceptible	
			Disk Diff	day	s since the last		Disk Diffusion (KB)	N/A
			Minimur PO		e culture (Feb/20)		Minimum inhibitory concentration (MIC)	N/A
			Final Interpret	ation	Susceptible		Final Interpretation	Susceptible
2018- 03-16	Blood	Minocycline	E-test		Less than 0.1 ug/ml Susceptible	Ceftazidime	E-test	Greater than 5.0 ug/ml Resistant
			Disk Diffusion (	KB)	Exactly equal to 2.5 mm Intermediate		Disk Diffusion (KB)	N/A
				inimum inhibitory Less than or equal to ncentration (MIC) 0.1 ug/ml Susceptible			Minimum inhibitory concentration (MIC)	N/A
			Final Interpret	ation	Susceptible		Final Interpretation	Resistant

Date	Source	Antimicrobial Agent	Test	Results	al agent	Test	Results
2018- 02-20	Blood	with	E-test	Greater than 5.0 ug/ml Resistant	Ceftazidime	E-test	Less than 0.1 ug/ml Susceptible
		Trimethoprim	Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate
			Minimum inhibitory concentration (MIC	N/A		Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible
			Final Interpretation	Resistant		Final Interpretation	Susceptible
2018- 02-24	CSF	Chloramphenicol	E-test	Less than 0.1 ug/ml Susceptible	Levofloxacin	E-test	Less than 0.1 ug/ml Susceptible
			Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	N/A		Minimum inhibitory concentration (MIC)	N/A
			Final Int Re	port to NHSN		Final Interpretation	Susceptible
2018- 03-16	Blood	Minocycline	E-test It has b	een more than 14	eftazidime	E-test	Greater than 5.0 ug/ml Resistant
			,			Disk Diffusion (KB)	N/A
			Mini nui concentration (MIC)	0.1 ug/ml Susceptible		Minimum inhibitory concentration (MIC)	N/A
			Final Interpretation	Susceptible		Final Interpretation	Resistant

# Walkthrough: 14 Day Rule Data Reported

					<del> </del>		
Date	Source	Antimicrobial Agent	Test	Results	Antimicrobi al agent	Test	Results
2018- 02-20	Blood	Sulfamethoxazole with Trimethoprim	E-test	Greater than 5.0 ug/ml Resistant	Ceftazidime	E-test	Less than 0.1 ug/ml Susceptible
			Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate
			Minimum inhibitory concentration (MIC	N/A		Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible
			Final Interpretation	Resistant		Final Interpretation	Susceptible
<del>2018-</del> <del>02-24</del>	CSF	Chloramphenicol	E-test	Less than 0.1 ug/ml Susceptible	Levofloxacin	E-test	Less than 0.1 ug/ml Susceptible
			<del>Disk Diffusion (KB)</del>	N/A		Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	N/A		Minimum inhibitory concentration (MIC)	<del>N/A</del>
			Final Interpretation	Susceptible		Final Interpretation	Susceptible
2018- 03-16	Blood	Minocycline	E-test	Less than 0.1 ug/ml Susceptible	Ceftazidime	E-test	Greater than 5.0 ug/ml Resistant
			Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate		Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible		Minimum inhibitory concentration (MIC)	N/A
			Final Interpretation	Susceptible		Final Interpretation	Resistant

#### Thank You


- Selecting Isolates
- Non-Invasive Steps
- Deduplication
- Full Overview



AR Reporting: Rules for reporting an Isolate from a non-invasive source

#### **CALCULATION WALKTHROUGH**






#### Non-Invasive Specimen Reporting

- Record an AR Event for:
  - First eligible organism isolated from an eligible non-invasive culture
  - Each patient
  - Each month
- NHSN only allows one AR event for lower respiratory or urine specimens per month per patient, per organism.



# Non Invasive Specimen Algorithm





#### Walkthrough: Selecting Non-Invasive

	vvaiktiiiougii. Scicetiiig ivoii iiivasive										
Date	Source	Antimicrobial Agent	Test	Results	Antimicrobi al agent	Test	Results				
2018- Urine 02-20	Sulfamethoxazole with Trimethoprim	E-test	Greater than 5.0 ug/ml Resistant	Ceftazidime	E-test	Less than 0.1 ug/ml Susceptible					
		Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	Exactly equal to 2.5					

N/A

N/A

N/A

Resistant

Susceptible

Susceptible

Susceptible

Susceptible

Less than 0.1 ug/ml

Exactly equal to 2.5

Less than or equal to

0.1 ug/ml Susceptible

mm Intermediate

Less than 0.1 ug/ml

2018-

02-21

2018-

03-01

Lower

Lower

ory

Respirat

Respirat ory

Chloramphenicol

Minocycline

Disk Diffusion (KB) N/A

Minimum inhibitory

concentration (MIC

**Final Interpretation** 

Disk Diffusion (KB)

Minimum inhibitory

concentration (MIC)

**Final Interpretation** 

Disk Diffusion (KB)

Minimum inhibitory

concentration (MIC)

**Final Interpretation** 

E-test

E-test

Levofloxacin

Ceftazidime

Minimum inhibitory

concentration (MIC)

**Final Interpretation** 

Disk Diffusion (KB)

Minimum inhibitory

concentration (MIC)

**Final Interpretation** 

Disk Diffusion (KB)

Minimum inhibitory

concentration (MIC)

**Final Interpretation** 

E-test

E-test

mm Intermediate

Susceptible

Susceptible

Susceptible

Greater than 5.0

ug/ml Resistant

N/A

N/A

N/A

N/A

Resistant

Less than or equal to

0.1 ug/ml Susceptible

Less than 0.1 ug/ml

#### Thank You

- Selecting Isolates
- Invasive Steps
- Deduplication
- High Level Overview



AR Reporting: Deduplication

#### **CALCULATION WALKTHROUGH**



#### **Duplicate Isolates**

- Duplicate Isolates
  - Defined as same species or same genus from same patient on same day
  - Isolates must have the same source type (i.e., invasive or non-invasive)
- Handling multiple isolates of the same organism
  - Isolates may produce conflicting results
  - Facilities should only report one isolate to NHSN
  - NHSN has rules for removing duplicates



#### General rules:

- Do not merge test results across multiple isolates
- Don't summarize results across different isolates tested on same day
- Eliminate isolates on same day without susceptibility test results
- For Invasive Specimens:
  - CSF isolates > blood isolates
- For Non-Invasive Specimens:
  - lower respiratory isolates > urine isolates



# Duplicate Isolate Scenarios: Conflicting Results

- 1. Same isolate tested using the same test, with conflicting results
- 2. Same isolate tested using different tests, with conflicting results
- 3. Two isolates collected on the same day return conflicting results from a panel of antimicrobial tests



- Same isolate, same specific test, conflicting results:
  - If available, report the final interpretation
  - Without a final interpretation, report the most resistant interpretation (i.e., NS > R > I > S-DD > S > NT)

#### Example:

- Interpretation of E-test 1 = Intermediate
- Interpretation of E-test 2 = Susceptible
- Report E-test 1/ Intermediate as final interpretation



- Same isolate, different specific tests, conflicting results:
  - If available, report the final interpretation
  - If no final interpretation is provided, report the most resistant interpretation (i.e., NS > R > I > S-DD > S > NT).

#### Example:

- Interpretation of MIC test = Resistant
- Interpretation of E-Test = Intermediate
- No final interpretation was provided
- Report "Resistant" as the final interpretation



- Different isolates, specific tests, conflicting results:
  - If available, report isolate with the most resistant final interpretation.
  - If no final interpretation, report the isolate with the higher amount of drug resistance based on the number antimicrobials testing "NS" or "R".
  - If all else fails, report first isolate entered into LIS
- Example: Candida albicans, isolated from two blood specimens, same patient, same calendar day, no final interpretation
  - First isolate tested "R" to 3 of 8 antimicrobials
  - Second isolate tested "R" to 4 of 8 antimicrobials
  - The facility reports the second isolate to NHSN because it showed greater resistance



# Walkthrough: Deduplication

Date	Source	Antimicrobial Agent	Test	Results	Antimicrobi al agent	Test	Results
2018- 02-20	Blood	Sulfamethoxazole with	E-test	Greater than 5.0 ug/ml Resistant	Ceftazidime	E-test	Less than 0.1 ug/ml Susceptible
		Trimethoprim	Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate
			Minimum inhibitory concentration (MIC	N/A		Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible
			Final Interpretation	Resistant		Final Interpretation	Susceptible
2018- 02-20	Blood	Sulfamethoxazole with Trimethoprim	E-test	Less than 0.1 ug/ml Susceptible	Ceftazidime	E-test	Greater than 5.0 ug/ml= Non- susceptible
			Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	N/A		Minimum inhibitory concentration (MIC)	N/A
		Final Interpretation	Susceptible		Final Interpretation	Non-Susceptible	

#### Scenario:

Two isolates from same day, conflicting results to panel of antimicrobials



# Walkthrough: Deduplication

Date	Source	Antimicrobial Agent	Test	Results		Antimicrobi al agent	Test	Results
2018- 02-20	Blood	Sulfamethoxa::ole with			) ug/ml	Ceftazidime	E-test	Less than 0.1 ug/ml Susceptible
		Trimethoprim	Collected on the same day				Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate
			22,				Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible
			rınaı interpretation	Kesistant			Final Interpretation	Susceptible
2018- 02-20	Blood	Sulfamethoxazole with Trimethoprim	E-test	Less than 0.1 ug Susceptible	g/ml	Ceftazidime	E-test	Greater than 5.0 ug/ml= Non- susceptible
			Disk Diffusion (KB)	N/A			Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	N/A			Minimum inhibitory concentration (MIC)	N/A
			Final Interpretation	Susceptible			Final Interpretation	Non-Susceptible



# Verification Walkthrough: Deduplication

			Test	Results	Antimicrobi al agent	Test	Results
Conflicting Results		E-test	Greater than 5.0 ug/ml Resistant	Ceftazidime	E-test	Less than 0.1 ug/ml Susceptible	
		Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate	
		Minimum inhibitory concentration (MIC	N/A		Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible	
			Final Interpretation	Resistant		Final Interpretation	Susceptible
2018- 02-20	Blood	Sulfamethoxazole with Trimethoprim	E-test	Less than 0.1 ug/ml Susceptible	Ceftazidime	E-test	Greater than 5.0 ug/ml= Non- susceptible
			Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	N/A		Minimum inhibitory concentration (MIC)	N/A
		<	Final Interpretation	Susceptible		Final Interpretation	Non-Susceptible



# Verification Walkthrough: Deduplication

Data	Cource	Antimicrobial	Test	Results	Antimicrobi	Tost	Results
Date	Source	Agent	rest	Results	al agent	Test	Results
2018- 02-20	Blood	Sulfamethoxazole with Trimethoprim	E-test	Greater than 5.0 ug/ml Resistant	Ceftazidime	E-test	Less than 0.1 ug/ml Susceptible
			Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate
			Minin	21/2		Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible
			Final			Final Interpretation	Susceptible
2018- 02-20	Blood	Sulfamethoxazole with Trimethoprim	<sub>E-test</sub> Report	most resistant result	Ceftazidime	E-test	Greater than 5.0 ug/ml= Non- susceptible
			Disk [			Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	N/A		Minimum inhibitory concentration (MIC)	N/A
			Final Interpretation	Susceptible		Final Interpretation	Non-Susceptible



# Verification Walkthrough: Deduplication Data Reported

Date	Source	Antimicrobial Agent	Test	Results	Antimicrobi al agent	Test	Results
<del>2018-</del> <del>02-20</del>	Blood	Sulfamethoxazole with	<del>E-test</del>	Greater than 5.0 ug/ml Resistant	Ceftazidime	E-test	Less than 0.1 ug/ml Susceptible
		Trimethoprim	Disk Diffusion (KB)	<del>N/A</del>		Disk Diffusion (KB)	Exactly equal to 2.5 mm Intermediate
			Minimum inhibitory concentration (MIC	N/A		Minimum inhibitory concentration (MIC)	Less than or equal to 0.1 ug/ml Susceptible
			Final Interpretation	Resistant		Final Interpretation	Susceptible
2018- 02-20	Blood	Sulfamethoxazole with Trimethoprim	E-test	Less than 0.1 ug/ml Susceptible	Ceftazidime	E-test	Greater than 5.0 ug/ml= Non- susceptible
			Disk Diffusion (KB)	N/A		Disk Diffusion (KB)	N/A
			Minimum inhibitory concentration (MIC)	N/A		Minimum inhibitory concentration (MIC)	N/A
			Final Interpretation	Susceptible		Final Interpretation	Non-Susceptible



#### Thank You


- Selecting Isolates
- Invasive Steps
- Non-Invasive Steps
- High-Level Overview



**AR Reporting** 

## NUMERATOR REPORTING: AN OVERVIEW





#### Thank You

- Selecting Isolates
- Invasive Steps
- Non-Invasive Steps
- Deduplication

